Compare Heron Therapeutics Inc (HRTX) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Lockheed Martin Corporation — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Lockheed Martin Corporation trades at $506.34 (market cap $117.48B). The key difference: Lockheed Martin Corporation is far larger — about 1284.5× Heron Therapeutics Inc's market cap, and Lockheed Martin Corporation pays a 2.71% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | LMT | |
|---|---|---|
Market Cap | $91.46M | $117.48B |
Sector | Health | Industrials |
52-Week High | $1.96 | $676.70 |
52-Week Low | $0.39 | $410.74 |
Enterprise Value | $189.36M | $136.28B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Lockheed Martin (LMT) trades at $509.44, showing modest daily gains of 0.13%. The stock faces bearish technical signals with recent earnings misses in Q4 2025 and Q1 2026, though Q3 2025 exceeded expectations. Revenue growth remains steady, reaching $75.05B in 2025, while net margins have compressed to 6.38%. Analyst sentiment is strongly positive with 57% buy ratings and a $614 consensus target, supported by recent contract wins and new product launches like the PAC-3 ACE interceptor.
LMT offers defensive exposure to elevated defense spending with a $194B backlog, but faces execution risks from margin pressure and debt levels. The stock trades at a premium 24.6x P/E with technical weakness near support at $504. Upside depends on Q2 earnings beat and defense budget sustainability amid geopolitical tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
